Remote Rehabilitation in Patients With HFpEF (PATRON-HF)
NCT07918209, Not applicable, Recruiting, American Heart of Poland
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Remote Rehabilitation in Patients With HFpEF (PATRON-HF) | ClinicalTrials.gov |
| NCT number | NCT07918209 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 110 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | American Heart of Poland | ClinicalTrials.gov |
| Conditions | Heart Failure With Preserved Ejection Fraction | ClinicalTrials.gov |
| Interventions | Telerehabilitation | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Efficacy | through study completion, an average of four months | Assessment of the efficacy of remote rehabilitation in patients with heart failure with preserved ejection fraction (HFpEF), assessed by the change in peak oxygen uptake (peak VO₂) measured by cardiopulmonary exercise testing (CPET) over a 3-month follow-up period. | ClinicalTrials.gov |
| Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | through study completion, an average of four months | Assessment of the safety of remote rehabilitation in patients with heart failure with preserved ejection fraction (HFpEF). | ClinicalTrials.gov |
| Secondary | Excercise capacity | through study completion, an average of four months | Assessment of exercise capacity using the 6-minute walk test (6MWT). | ClinicalTrials.gov |
| Secondary | NT-proBNP | through study completion, an average of four months | Assessment of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. | ClinicalTrials.gov |
| Secondary | Quality of life (Kansas City Cardiomyopathy Questionnaire) | through study completion, an average of four months | Assessment of patients' quality of life using the Kansas City Cardiomyopathy Questionnaire, where minimum value is 0 and maximum value is 100; higher scores mean: better outcome (fewer heart failure symptoms, fewer physical and social limitations, and better quality of life). | ClinicalTrials.gov |
| Secondary | Quality of life (EuroQol-5D | through study completion, an average of four months | Assessment of patients' quality of life using the EuroQol-5D questionnaire, where minimum value is 0 and maximum value is 100; higher scores mean: better health status and health-related quality of life | ClinicalTrials.gov |
| Other | Level of adipokines | through study completion, an average of four months | Percentage change in serum concentrations of adipose tissue-derived hormones: leptin, visfatin, adiponectin, resistin, omentin, and apelin measured in ng/mL. | ClinicalTrials.gov |
| Other | Level of inflammatory markers measured in ng/mL. | through study completion, an average of four months | Percentage change in serum concentrations of oxidative stress and inflammatory markers: Myeloperoxidase, calprotectin, symmetric and asymmetric dimethylarginine (SDMA, ADMA), arginine measured in ng/mL. | ClinicalTrials.gov |
| Other | Liver elastography | through study completion, an average of four months | Liver stiffness will be assessed by elastography and reported as the median of 10 measurements. Unit of Measure: kPa. | ClinicalTrials.gov |
| Other | Level of inflammatory markers measured in mg/mL. | through study completion, an average of four months | Percentage change in serum concentrations of oxidative stress and inflammatory markers: hsCRP, indoxyl sulfate and trimethylamine N-oxide (TMAO) measured in mg/mL. | ClinicalTrials.gov |
| Other | Level of inflammatory marker measured in mU/mL. | through study completion, an average of four months | Percentage change in serum activity of oxidative stress and inflammatory marker: myeloperoxidase measured in mU/mL. | ClinicalTrials.gov |
| Other | Level of inflammatory marker measured in mg/dl | through study completion, an average of four months | Percentage change in serum concentrations of oxidative stress and inflammatory marker: uric acid measured in mg/dl. | ClinicalTrials.gov |
| Other | Level of inflammatory markers measured in pg/ml | through study completion, an average of four months | Percentage change in serum concentrations of oxidative stress and inflammatory marker: interleukin 6 measured in pg/ml | ClinicalTrials.gov |
| Other | Index of Microcirculatory Resistance (IMR) | through study completion, an average of four months | The Index of Microcirculatory Resistance (IMR) will be assessed during invasive coronary physiological evaluation using a pressure- and temperature-sensing coronary guidewire. IMR will be defined as the product of distal coronary pressure and the mean transit time of a saline bolus during maximal hyperemia, measured using a dual-function pressure- and temperature-sensing guidewire. IMR is a specific index reflecting coronary microvascular function. | ClinicalTrials.gov |
| Other | Coronary Flow Reserve (CRF) | through study completion, an average of four months | Coronary flow reserve (CFR) will be assessed during invasive coronary physiological evaluation using a pressure- and temperature-sensing coronary guidewire. CFR will be defined as the ratio of maximal to baseline coronary blood flow. It will measure the capacity of both the epicardial artery and the microvascular resistance vessels to facilitate blood flow. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 4
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)